Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement

Matteo Di Nardo; Ali H. Ahmad; Pietro Merli; Matthew S. Zinter; Leslie E. Lehman; Courtney M. Rowan; Marie E. Steiner; Sangeeta Hingorani; Joseph R. Angelo; Hisham Abdel-Azim; Sajad J. Khazal; Basirat Shoberu; Jennifer McArthur; Rajinder Bajwa; Saad Ghafoor; Samir H. Shah; Hitesh Sandhu; Karen Moody; Brandon D. Brown; Maria E. Mireles; Diana Steppan; Taylor Olson; Lakshmi Raman; Brian Bridges; Christine N. Duncan; Sung Won Choi; Rita Swinford; Matt Paden; James D. Fortenberry; Giles Peek; Pierre Tissieres; Daniele De Luca; Franco Locatelli; Selim Corbacioglu; Martin Kneyber; Alessio Franceschini; Simon Nadel; Matthias Kumpf; Alessandra Loreti; Roelie Wösten-Van Asperen; Orsola Gawronski; Joe Brierley; Graeme MacLaren; Kris M. Mahadeo

doi:10.1016/S2352-4642(21)00336-9

Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement

Matteo Di Nardo, Ali H. Ahmad, Pietro Merli, Matthew S. Zinter, Leslie E. Lehman, Courtney M. Rowan, Marie E. Steiner, Sangeeta Hingorani, Joseph R. Angelo, Hisham Abdel-Azim, Sajad J. Khazal, Basirat Shoberu, Jennifer McArthur, Rajinder Bajwa, Saad Ghafoor, Samir H. Shah, Hitesh Sandhu, Karen Moody, Brandon D. Brown, Maria E. MirelesDiana Steppan, Taylor Olson, Lakshmi Raman, Brian Bridges, Christine N. Duncan, Sung Won Choi, Rita Swinford, Matt Paden, James D. Fortenberry, Giles Peek, Pierre Tissieres, Daniele De Luca, Franco Locatelli, Selim Corbacioglu, Martin Kneyber, Alessio Franceschini, Simon Nadel, Matthias Kumpf, Alessandra Loreti, Roelie Wösten-Van Asperen, Orsola Gawronski, Joe Brierley, Graeme MacLaren, Kris M. Mahadeo

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Use of extracorporeal membrane oxygenation (ECMO) in children receiving haematopoietic cell transplantation (HCT) and immune effector cell therapy is controversial and evidence-based guidelines have not been established. Remarkable advancements in HCT and immune effector cell therapies have changed expectations around reversibility of organ dysfunction and survival for affected patients. Herein, members of the Extracorporeal Life Support Organization (ELSO), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network (HCT and cancer immunotherapy subgroup), the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT), the supportive care committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC), and the Pediatric Intensive Care Oncology Kids in Europe Research (POKER) group of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) provide consensus recommendations on the use of ECMO in children receiving HCT and immune effector cell therapy. These are the first international, multidisciplinary consensus-based recommendations on the use of ECMO in this patient population. This Review provides a clinical decision support tool for paediatric haematologists, oncologists, and critical care physicians during the difficult decision-making process of ECMO candidacy and management. These recommendations can represent a base for future research studies focused on ECMO selection criteria and bedside management.

Original language	English (US)
Pages (from-to)	116-128
Number of pages	13
Journal	The Lancet Child and Adolescent Health
Volume	6
Issue number	2
DOIs	https://doi.org/10.1016/S2352-4642(21)00336-9
State	Published - Feb 2022

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Developmental and Educational Psychology

Access to Document

10.1016/S2352-4642(21)00336-9

Cite this

Di Nardo, M., Ahmad, A. H., Merli, P., Zinter, M. S., Lehman, L. E., Rowan, C. M., Steiner, M. E., Hingorani, S., Angelo, J. R., Abdel-Azim, H., Khazal, S. J., Shoberu, B., McArthur, J., Bajwa, R., Ghafoor, S., Shah, S. H., Sandhu, H., Moody, K., Brown, B. D., ... Mahadeo, K. M. (2022). Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement. The Lancet Child and Adolescent Health, 6(2), 116-128. https://doi.org/10.1016/S2352-4642(21)00336-9

Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement. / Di Nardo, Matteo; Ahmad, Ali H.; Merli, Pietro et al.
In: The Lancet Child and Adolescent Health, Vol. 6, No. 2, 02.2022, p. 116-128.

Research output: Contribution to journal › Review article › peer-review

Di Nardo, M, Ahmad, AH, Merli, P, Zinter, MS, Lehman, LE, Rowan, CM, Steiner, ME, Hingorani, S, Angelo, JR, Abdel-Azim, H, Khazal, SJ, Shoberu, B, McArthur, J, Bajwa, R, Ghafoor, S, Shah, SH, Sandhu, H, Moody, K, Brown, BD, Mireles, ME, Steppan, D, Olson, T, Raman, L, Bridges, B, Duncan, CN, Choi, SW, Swinford, R, Paden, M, Fortenberry, JD, Peek, G, Tissieres, P, De Luca, D, Locatelli, F, Corbacioglu, S, Kneyber, M, Franceschini, A, Nadel, S, Kumpf, M, Loreti, A, Wösten-Van Asperen, R, Gawronski, O, Brierley, J, MacLaren, G & Mahadeo, KM 2022, 'Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement', The Lancet Child and Adolescent Health, vol. 6, no. 2, pp. 116-128. https://doi.org/10.1016/S2352-4642(21)00336-9

@article{99f9bd7a08dd4a4e9e495708c22611c5,

title = "Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement",

abstract = "Use of extracorporeal membrane oxygenation (ECMO) in children receiving haematopoietic cell transplantation (HCT) and immune effector cell therapy is controversial and evidence-based guidelines have not been established. Remarkable advancements in HCT and immune effector cell therapies have changed expectations around reversibility of organ dysfunction and survival for affected patients. Herein, members of the Extracorporeal Life Support Organization (ELSO), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network (HCT and cancer immunotherapy subgroup), the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT), the supportive care committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC), and the Pediatric Intensive Care Oncology Kids in Europe Research (POKER) group of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) provide consensus recommendations on the use of ECMO in children receiving HCT and immune effector cell therapy. These are the first international, multidisciplinary consensus-based recommendations on the use of ECMO in this patient population. This Review provides a clinical decision support tool for paediatric haematologists, oncologists, and critical care physicians during the difficult decision-making process of ECMO candidacy and management. These recommendations can represent a base for future research studies focused on ECMO selection criteria and bedside management.",

author = "{Di Nardo}, Matteo and Ahmad, {Ali H.} and Pietro Merli and Zinter, {Matthew S.} and Lehman, {Leslie E.} and Rowan, {Courtney M.} and Steiner, {Marie E.} and Sangeeta Hingorani and Angelo, {Joseph R.} and Hisham Abdel-Azim and Khazal, {Sajad J.} and Basirat Shoberu and Jennifer McArthur and Rajinder Bajwa and Saad Ghafoor and Shah, {Samir H.} and Hitesh Sandhu and Karen Moody and Brown, {Brandon D.} and Mireles, {Maria E.} and Diana Steppan and Taylor Olson and Lakshmi Raman and Brian Bridges and Duncan, {Christine N.} and Choi, {Sung Won} and Rita Swinford and Matt Paden and Fortenberry, {James D.} and Giles Peek and Pierre Tissieres and {De Luca}, Daniele and Franco Locatelli and Selim Corbacioglu and Martin Kneyber and Alessio Franceschini and Simon Nadel and Matthias Kumpf and Alessandra Loreti and {W{\"o}sten-Van Asperen}, Roelie and Orsola Gawronski and Joe Brierley and Graeme MacLaren and Mahadeo, {Kris M.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = feb,

doi = "10.1016/S2352-4642(21)00336-9",

language = "English (US)",

volume = "6",

pages = "116--128",

journal = "The Lancet Child and Adolescent Health",

issn = "2352-4642",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy

T2 - an international and multidisciplinary consensus statement

AU - Di Nardo, Matteo

AU - Ahmad, Ali H.

AU - Merli, Pietro

AU - Zinter, Matthew S.

AU - Lehman, Leslie E.

AU - Rowan, Courtney M.

AU - Steiner, Marie E.

AU - Hingorani, Sangeeta

AU - Angelo, Joseph R.

AU - Abdel-Azim, Hisham

AU - Khazal, Sajad J.

AU - Shoberu, Basirat

AU - McArthur, Jennifer

AU - Bajwa, Rajinder

AU - Ghafoor, Saad

AU - Shah, Samir H.

AU - Sandhu, Hitesh

AU - Moody, Karen

AU - Brown, Brandon D.

AU - Mireles, Maria E.

AU - Steppan, Diana

AU - Olson, Taylor

AU - Raman, Lakshmi

AU - Bridges, Brian

AU - Duncan, Christine N.

AU - Choi, Sung Won

AU - Swinford, Rita

AU - Paden, Matt

AU - Fortenberry, James D.

AU - Peek, Giles

AU - Tissieres, Pierre

AU - De Luca, Daniele

AU - Locatelli, Franco

AU - Corbacioglu, Selim

AU - Kneyber, Martin

AU - Franceschini, Alessio

AU - Nadel, Simon

AU - Kumpf, Matthias

AU - Loreti, Alessandra

AU - Wösten-Van Asperen, Roelie

AU - Gawronski, Orsola

AU - Brierley, Joe

AU - MacLaren, Graeme

AU - Mahadeo, Kris M.

PY - 2022/2

Y1 - 2022/2

N2 - Use of extracorporeal membrane oxygenation (ECMO) in children receiving haematopoietic cell transplantation (HCT) and immune effector cell therapy is controversial and evidence-based guidelines have not been established. Remarkable advancements in HCT and immune effector cell therapies have changed expectations around reversibility of organ dysfunction and survival for affected patients. Herein, members of the Extracorporeal Life Support Organization (ELSO), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network (HCT and cancer immunotherapy subgroup), the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT), the supportive care committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC), and the Pediatric Intensive Care Oncology Kids in Europe Research (POKER) group of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) provide consensus recommendations on the use of ECMO in children receiving HCT and immune effector cell therapy. These are the first international, multidisciplinary consensus-based recommendations on the use of ECMO in this patient population. This Review provides a clinical decision support tool for paediatric haematologists, oncologists, and critical care physicians during the difficult decision-making process of ECMO candidacy and management. These recommendations can represent a base for future research studies focused on ECMO selection criteria and bedside management.

AB - Use of extracorporeal membrane oxygenation (ECMO) in children receiving haematopoietic cell transplantation (HCT) and immune effector cell therapy is controversial and evidence-based guidelines have not been established. Remarkable advancements in HCT and immune effector cell therapies have changed expectations around reversibility of organ dysfunction and survival for affected patients. Herein, members of the Extracorporeal Life Support Organization (ELSO), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network (HCT and cancer immunotherapy subgroup), the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT), the supportive care committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC), and the Pediatric Intensive Care Oncology Kids in Europe Research (POKER) group of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) provide consensus recommendations on the use of ECMO in children receiving HCT and immune effector cell therapy. These are the first international, multidisciplinary consensus-based recommendations on the use of ECMO in this patient population. This Review provides a clinical decision support tool for paediatric haematologists, oncologists, and critical care physicians during the difficult decision-making process of ECMO candidacy and management. These recommendations can represent a base for future research studies focused on ECMO selection criteria and bedside management.

UR - http://www.scopus.com/inward/record.url?scp=85122921646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122921646&partnerID=8YFLogxK

U2 - 10.1016/S2352-4642(21)00336-9

DO - 10.1016/S2352-4642(21)00336-9

M3 - Review article

C2 - 34895512

AN - SCOPUS:85122921646

SN - 2352-4642

VL - 6

SP - 116

EP - 128

JO - The Lancet Child and Adolescent Health

JF - The Lancet Child and Adolescent Health

IS - 2

ER -

Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this